Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.49 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119403 | 0.99 | TGM2 (0.61) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL18087519 | 0.91 | TGM2 (0.62) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL17399553 | 0.89 | TGM2 (0.65) | TGM2MEN1USP2POLBPPARG | |
| Piperazine SCHEMBL1317991 | 0.89 | MEN1 (0.55) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL18540754 | 0.88 | TGM2 (0.48) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL12870952 | 0.88 | TGM2 (0.60) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL18067135 | 0.87 | TGM2 (0.60) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL13103120 | 0.87 | TGM2 (0.61) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL18732968 | 0.87 | TGM2 (0.61) | TGM2MEN1USP2POLBPPARG | |
| SCHEMBL13114580 | 0.86 | TGM2 (0.59) | TGM2MEN1USP2POLBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
| EP-3137554-A1 | AZOARYLS AS REVERSIBLY MODULATABLE TUBULIN INHIBITORS | Ecole Normale Superieure De Lyon (FR) | 2017-03-08 | — | — | EP | disclosed |
| US-20170051149-A1 | AZOARYLS AS REVERSIBLY MODULATABLE TUBULIN INHIBITORS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2017-02-23 | — | — | US | disclosed |
| EP-3122758-A1 | NOVEL KLK4 INHIBITORS | Universiteit Antwerpen (BE) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015166295-A1 | AZOARYLS AS REVERSIBLY MODULATABLE TUBULIN INHIBITORS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015144933-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2015-10-01 | — | — | WO | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| EP-2707034-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | Universiteit Antwerpen (BE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | KLK4, KLK3, KLK1 | CHRM1 1172/4885TGM2 944/4885MEN1 3183/4885 |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | CHRM1 4830/4885TGM2 343/4885MEN1 2509/4885 |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | KLK4, KLK3, KLK1 | CHRM1 1155/4885TGM2 718/4885MEN1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.